Vyne aims to raise $88M; Sanofi invests in gene therapy company; 4DMT addresses clinical holdnews2023-10-30T15:01:27+00:00October 30th, 2023|Endpoints News|
Viridian Therapeutics hires three Magenta executives, replaces CEO and signs $185M private placementnews2023-10-30T14:47:57+00:00October 30th, 2023|Endpoints News|
Gene therapy biotech Lexeo Therapeutics eyes $113M in Nasdaq IPO proceedsnews2023-10-30T12:54:42+00:00October 30th, 2023|Endpoints News|
Vir eyes expansion beyond infectious diseases and into oncology, neurology with new leadershipnews2023-10-30T12:05:28+00:00October 30th, 2023|Endpoints News|
Merck KGaA pays $169M upfront in deal for Hengrui’s PARP1 inhibitor and ADCnews2023-10-30T11:34:29+00:00October 30th, 2023|Endpoints News|
MapLight raises $225M in bid to make better schizophrenia drug than pathfinder Karuna news2023-10-30T11:30:52+00:00October 30th, 2023|Endpoints News|
Abingworth secures $356M to help Big Pharma expand drug labels, support PhIII trialsnews2023-10-30T08:00:33+00:00October 30th, 2023|Endpoints News|
GSK’s checkpoint inhibitor plus chemotherapy prolongs survival for endometrial cancer patients in PhIII studynews2023-10-30T06:00:55+00:00October 30th, 2023|Endpoints News|
Roche’s $7.1B bet on Roivant drug; ADCs and other #ESMO23 dispatch; Highlights from Alzheimer’s confab; Q3 pharma drama; and morenews2023-10-28T10:00:11+00:00October 28th, 2023|Endpoints News|
Another Eylea threat: Roche expands label for blockbuster eye drug Vabysmonews2023-10-27T19:01:11+00:00October 27th, 2023|Endpoints News|
